Marshall Wace
ZYNE

Marshall Wace’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Marshall Wace’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,364
Closed -$155K – 3257
2021
Q1 		$155K Buy
+33,364
New +$151K ﹤0.01% 2311

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's ZYNE Position: Q2 2021 in Review

Marshall Wace sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2021, closing a stake of 33,364 shares — an estimated $155K sold.

Marshall Wace first reported a position in ZYNE in Q1 2021 and held it in 1 quarter. The position peaked at $155K in Q1 2021. 65 funds tracked by Wall St. Rank hold ZYNE as of Q2 2021.

  • Marshall Wace reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace sold 33,364 Zynerba Pharmaceuticals, Inc shares in Q2 2021, an estimated $155K.
  • Marshall Wace first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2021 and held it in 1 quarter.
  • Marshall Wace's Zynerba Pharmaceuticals, Inc position peaked at $155K in Q1 2021.
  • 65 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.